COLAGROSSI, LUNA
 Distribuzione geografica
Continente #
NA - Nord America 1.611
EU - Europa 208
AS - Asia 111
OC - Oceania 3
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.936
Nazione #
US - Stati Uniti d'America 1.611
IT - Italia 69
IE - Irlanda 59
KR - Corea 49
SG - Singapore 36
CN - Cina 19
DE - Germania 17
GB - Regno Unito 11
CZ - Repubblica Ceca 9
FR - Francia 9
SE - Svezia 8
UA - Ucraina 8
RU - Federazione Russa 6
FI - Finlandia 5
IN - India 5
AU - Australia 3
BE - Belgio 3
A2 - ???statistics.table.value.countryCode.A2??? 1
BR - Brasile 1
CH - Svizzera 1
CL - Cile 1
ES - Italia 1
GR - Grecia 1
PL - Polonia 1
TR - Turchia 1
VN - Vietnam 1
Totale 1.936
Città #
Wilmington 486
Houston 345
Woodbridge 132
Fairfield 111
Chandler 102
Dublin 44
Ashburn 40
Seattle 38
New York 32
Rome 30
Ann Arbor 29
Cambridge 29
Singapore 27
Medford 26
Dearborn 18
Beijing 14
Lawrence 12
Engelhard 10
Menlo Park 10
Munich 10
Milan 9
San Diego 8
San Jose 7
Santa Clara 7
Creede 6
St. George 6
Cedarhurst 5
Colorado Springs 5
Helsinki 5
Nepi 5
Olomouc 5
Brno 4
London 4
Los Angeles 4
Brussels 3
Kilburn 3
Moscow 3
Palo Alto 3
Albano Laziale 2
Bari 2
Bengaluru 2
Bollate 2
Durham 2
Jacksonville 2
Pune 2
Roebling 2
San Francisco 2
Seoul 2
Athens 1
Belgrade 1
Canberra 1
Clearwater 1
Council Bluffs 1
Geislingen an der Steige 1
Guangzhou 1
Hefei 1
Hounslow 1
Kraków 1
Leawood 1
Madrid 1
Melbourne 1
Mountain View 1
Mülheim 1
Nanchang 1
Nanjing 1
North Hollywood 1
Saint Petersburg 1
San Severo 1
Sydney 1
São Paulo 1
Totale 1.679
Nome #
Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal 389
High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance 320
HDV can constrain HBV genetic evolution in hbsag: Implications for the identification of innovative pharmacological targets 283
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe 202
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection 171
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro 167
Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection 98
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases 57
BNT162B2 mRNA COVID-19 Vaccine in Heart and Lung Transplanted Young Adults: Is an Alternative SARS-CoV-2 Immune Response Surveillance Needed? 49
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B 42
Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome 37
An increase in the levels of middle surface antigen characterizes patients developing HBV-driven liver cancer despite prolonged virological suppression 35
Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies 32
Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment 27
Evaluation of Safety and Immunogenicity of BNT162B2 mRNA COVID-19 Vaccine in IBD Pediatric Population with Distinct Immune Suppressive Regimens 25
Highly specific memory b cells generation after the 2nd dose of bnt162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal iga 25
Genetic signatures specifically clustered in immune active HBsAg regions correlate with immunosuppression-driven HBV reactivation: An extensive analysis of HBV genome. 20
Perinatally Human Immunodeficiency Virus-Infected Adolescents and Young Adults Demonstrate Distinct BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Immunogenicity 17
Influenza viruses circulation in a tertiary care children hospital in Rome: a comparison between 2022 and the previous 5 years 9
Humoral and cellular immunogenicity and safety up to 4 months after vaccination with BNT162B2 mRNA COVID-19 vaccine in heart and lung transplanted young adults 2
Totale 2.007
Categoria #
all - tutte 7.215
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.215


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020528 0 40 35 47 46 66 54 45 72 43 40 40
2020/2021341 34 30 39 36 30 42 61 39 7 9 7 7
2021/2022168 1 8 0 7 20 6 11 1 61 12 6 35
2022/2023330 20 28 25 21 42 49 42 29 31 9 28 6
2023/2024147 12 21 13 5 19 28 15 4 2 11 1 16
2024/202562 17 45 0 0 0 0 0 0 0 0 0 0
Totale 2.007